Autolus Therapeutics Files Q1 2024 10-Q
Ticker: AUTL · Form: 10-Q · Filed: 2024-05-17T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotech, financials
TL;DR
Autolus Q1 10-Q filed. Financials and ops update.
AI Summary
Autolus Therapeutics plc filed a 10-Q for the period ending March 31, 2024. The company reported its financial results and operational highlights. Key financial data and business updates are detailed within the filing.
Why It Matters
This filing provides investors with a quarterly update on Autolus Therapeutics' financial health and operational progress, crucial for understanding the company's trajectory in the biopharmaceutical sector.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Autolus Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 Q1 — Reporting Period (First quarter of 2024)
- 12/31 — Fiscal Year End (Indicates the company's fiscal year concludes on December 31st)
Key Players & Entities
- Autolus Therapeutics plc (company) — Filer of the 10-Q
- 20240331 (date) — End of the reporting period
- 20240517 (date) — Filing date
FAQ
What is the primary business of Autolus Therapeutics plc?
Autolus Therapeutics plc is involved in the development of biological products, specifically in the area of biological products (no diagnostic substances).
What is the SEC file number for Autolus Therapeutics plc?
The SEC file number for Autolus Therapeutics plc is 001-38547.
What is the address of Autolus Therapeutics plc?
The business address for Autolus Therapeutics plc is THE MEDIAWORKS, 191 WOOD LANE, LONDON, W12 7FP.
When was Autolus Therapeutics plc formerly known as Autolus Therapeutics Ltd?
The company was formerly known as Autolus Therapeutics Ltd, with a date of name change on 20180205.
What is the standard industrial classification for Autolus Therapeutics plc?
The Standard Industrial Classification for Autolus Therapeutics plc is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
From the Filing
0001730463-24-000064.txt : 20240517 0001730463-24-000064.hdr.sgml : 20240517 20240517163900 ACCESSION NUMBER: 0001730463-24-000064 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24960511 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 10-Q 1 autl-20240331.htm 10-Q autl-20240331 0001730463 false 2024 Q1 12/31 True 823 xbrli:shares iso4217:USD iso4217:USD xbrli:shares iso4217:GBP xbrli:shares xbrli:pure autl:financialInstrument autl:unit autl:performanceObligation autl:vote autl:payment autl:contract iso4217:EUR autl:director 0001730463 2024-01-01 2024-03-31 0001730463 dei:AdrMember 2024-01-01 2024-03-31 0001730463 autl:OrdinarySharesMember 2024-01-01 2024-03-31 0001730463 2024-05-13 0001730463 2024-03-31 0001730463 2023-12-31 0001730463 autl:OrdinarySharesMember 2023-12-31 0001730463 autl:OrdinarySharesMember 2024-03-31 0001730463 autl:DeferredClassASharesMember 2023-12-31 0001730463 autl:DeferredClassASharesMember 2024-03-31 0001730463 autl:DeferredClassBSharesMember 2024-03-31 0001730463 autl:DeferredClassBSharesMember 2023-12-31 0001730463 autl:DeferredClassCSharesMember 2024-03-31 0001730463 autl:DeferredClassCSharesMember 2023-12-31 0001730463 us-gaap:LicenseMember 2024-01-01 2024-03-31 0001730463 us-gaap:LicenseMember 2023-01-01 2023-03-31 0001730463 2023-01-01 2023-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2023-12-31 0001730463 autl:DeferredClassASharesMember us-gaap:CommonStockMember 2023-12-31 0001730463 autl:DeferredClassBSharesMember us-gaap:CommonStockMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2023-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001730463 us-gaap:RetainedEarningsMember 2023-12-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-01-01 2024-03-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001730463 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2024-03-31 0001730463 autl:DeferredClassASharesMember us-gaap:CommonStockMember 2024-03-31 0001730463 autl:DeferredClassBSharesMember us-gaap:CommonStockMember 2024-03-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2024-03-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001730463 us-gaap:RetainedEarningsMember 2024-03-31 0001730463 us-gaap:CommonStockMember autl:OrdinarySharesMember 2022-12-31 0001730463 autl:DeferredClassASharesMember us-gaap:CommonStockMember 2022-12-31 0001730463 autl:DeferredClassBSharesMember us-gaap:CommonStockMember 2022-12-31 0001730463 us-gaap:CommonStockMember autl:DeferredClassCSharesMember 2022-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001730463 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001730463 us-gaap:RetainedEarningsMember 2022-12-31 0001730463 2022-12-31 0001730463 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001730463 us-gaap:AccumulatedOtherCompr